<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/lyon-economic-news/pharmaceutique_biotech-news-BIOASTER-A-TARGETED-APPROACH-TO-INFECTIOUS-DISEASES-AND-MICROBIOLOGY,n,6732,EN.jsp" target=_blank>The Bioaster Technology Research Institute&#8217;s strategy </A></STRONG>is based on three product-oriented research projects: new therapies and vaccines, diagnostics and microbiota.</STRONG></P> <P align=justify><BR>The Bioaster TRI provides <STRONG>six technology centers and 13 technical platforms for the development of these cutting-edge research programs</STRONG> (in genomics and trasncriptomics, structural biology, proteomics, metabolomics, immunomonitoring, bioproduction, chemical synthesis, high-speed screening, animal models, imaging, micro and nanotechnology, and information and knowledge technology).</P> <P align=justify><BR><STRONG>It aims to firmly establish <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>healthcare companies in France</A></STRONG>, to develop the network of local SMEs, to foster the emergence of medium-sized businesses, and to help train specialized personnel, eventually providing several hundred researchers for tomorrow&#8217;s biotech fields in order to meet new public health challenges. </P> <P align=justify><BR>The R&amp;D projects and the search for public-private partnerships have already started. <STRONG>The aim is to launch some 40 R&amp;D projects within the next three years. </STRONG></P> <P align=justify><BR>The initial Founders have promised to provide Bioaster&#8217;s Scientific Cooperation Foundation with &#8364;7.3 million. Based on an overall budget of &#8364;585 million over 9 years, including &#8364;90 for the next three years, the French State will provide a maximum of &#8364;180 million, to be supplemented by funding from private partners and European bodies.</P> <P>&nbsp;</P> <P>Source: <A href="http://www.bioaster.com/">www.bioaster.com</A><BR></P>